Pugsley M K, Authier S, Curtis M J
Department of Toxicology & Pathology, Global Preclinical Development, Johnson & Johnson Pharmaceutical Research & Development, Raritan, NJ, USA.
Br J Pharmacol. 2008 Aug;154(7):1382-99. doi: 10.1038/bjp.2008.280. Epub 2008 Jul 7.
Safety Pharmacology is a rapidly developing discipline that uses the basic principles of pharmacology in a regulatory-driven process to generate data to inform risk/benefit assessment. The aim of Safety Pharmacology is to characterize the pharmacodynamic/pharmacokinetic (PK/PD) relationship of a drug's adverse effects using continuously evolving methodology. Unlike toxicology, Safety Pharmacology includes within its remit a regulatory requirement to predict the risk of rare lethal events. This gives Safety Pharmacology its unique character. The key issues for Safety Pharmacology are detection of an adverse effect liability, projection of the data into safety margin calculation and finally clinical safety monitoring. This article sets out to explain the drivers for Safety Pharmacology so that the wider pharmacology community is better placed to understand the discipline. It concludes with a summary of principles that may help inform future resolution of unmet needs (especially establishing model validation for accurate risk assessment). Subsequent articles in this issue of the journal address specific aspects of Safety Pharmacology to explore the issues of model choice, the burden of proof and to highlight areas of intensive activity (such as testing for drug-induced rare event liability, and the challenge of testing the safety of so-called biologics (antibodies, gene therapy and so on.).
安全药理学是一门快速发展的学科,它在监管驱动的过程中运用药理学的基本原理来生成数据,以辅助风险/效益评估。安全药理学的目的是使用不断发展的方法来描述药物不良反应的药效学/药代动力学(PK/PD)关系。与毒理学不同,安全药理学的职责范围内包含预测罕见致死事件风险的监管要求。这赋予了安全药理学独特的性质。安全药理学的关键问题包括检测不良反应倾向、将数据用于安全边际计算以及最终的临床安全监测。本文旨在解释安全药理学的驱动因素,以便更广泛的药理学界能更好地理解这一学科。文章最后总结了一些原则,这些原则可能有助于为未来未满足需求的解决提供参考(特别是为准确的风险评估建立模型验证)。本期杂志的后续文章将探讨安全药理学的具体方面,以研究模型选择问题、举证责任,并突出重点研究领域(如检测药物引起罕见事件的倾向,以及检测所谓生物制品(抗体、基因治疗等)安全性的挑战)。